Literature DB >> 8452355

Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.

P A Bradford1, C C Sanders.   

Abstract

A predictor panel of clinical isolates that produce a variety of types and amounts of beta-lactamases was used to assess the accuracies of a variety of susceptibility tests for ampicillin-sulbactam. Combinations of ampicillin-sulbactam in ratios of 1:1 and 2:1 and with sulbactam held constant at concentrations of 4 and 8 micrograms/ml were examined in dilution tests performed in agar and broth. In addition, disks containing 10/10, 20/10, 20/20, and 20/30 micrograms of ampicillin-sulbactam were examined in diffusion tests. The results indicated that the MICs obtained in broth microdilution tests performed with each of the four combinations differed, on average, less than twofold. Of the disks tested, the 20/10-micrograms ampicillin-sulbactam disk provided the best separation between susceptible and resistant strains when interpretive criteria for resistance was a zone size of < or = 16 mm and that for susceptibility was a zone size of > or = 21 mm. This disk also gave the highest overall agreement with MICs, regardless of the combination used in the broth microdilution test. Discrepancies between agar and broth microdilution MICs were greater than twofold, on average, and this necessitated recommendation of separate criteria for the two methods. Thus, a predictor panel was very useful in identifying the parameters of susceptibility tests that were most accurate in identifying strains that were susceptible and resistant to ampicillin-sulbactam.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452355      PMCID: PMC187648          DOI: 10.1128/AAC.37.2.251

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Penetration of ampicillin and sulbactam in the lower airways during respiratory infections.

Authors:  Y J Valcke; M T Rosseel; R A Pauwels; M G Bogaert; M E Van der Straeten
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

4.  Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics.

Authors:  C C Sanders; W E Sanders
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

5.  Characterization of beta-lactamases in situ on polyacrylamide gels.

Authors:  C C Sanders; W E Sanders; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

6.  Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

7.  Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.

Authors:  C C Sanders; J P Iaconis; G P Bodey; G Samonis
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

8.  Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

Review 9.  Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

Authors:  D M Campoli-Richards; R N Brogden
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

10.  Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers.

Authors:  B R Meyers; P Wilkinson; M H Mendelson; S Walsh; C Bournazos; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

View more
  6 in total

1.  A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Authors:  Patricia A Bradford; Michael D Huband; Gregory G Stone
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  Response of enteric gram-negative bacteria to disks containing 20 micrograms each of ampicillin and sulbactam.

Authors:  H D Isenberg; P Alperstein; K France
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

3.  Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

4.  Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions.

Authors:  M Alexov; P D Lister; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

5.  Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance.

Authors:  K C Lamp; M K Vickers
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.

Authors:  Peter J Petersen; C Hal Jones; Aranapakam M Venkatesan; Tarek S Mansour; Steven J Projan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.